Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours

[1]  D. Generali,et al.  Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[2]  B. Fadeel,et al.  PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells , 2016, Oncotarget.

[3]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[4]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[5]  A. Jazirehi,et al.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. , 2016, American journal of cancer research.

[6]  K. Rezvani,et al.  The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer , 2015, Front. Immunol..

[7]  Y. Naito,et al.  Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer , 2015, Journal of Translational Medicine.

[8]  S. Selvan,et al.  “Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy , 2015, BioMed research international.

[9]  A. Björklund,et al.  Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors , 2015, Front. Immunol..

[10]  S. Granjeaud,et al.  Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer , 2015, Oncotarget.

[11]  Nicholas K. Brown,et al.  CD160 is essential for NK-mediated IFN-γ production , 2015, The Journal of experimental medicine.

[12]  D. Campana,et al.  Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients , 2015, Journal of immunotherapy.

[13]  Jeffrey S. Miller,et al.  Clinical utility of natural killer cells in cancer therapy and transplantation. , 2014, Seminars in immunology.

[14]  Sun-Hee Kim,et al.  Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation , 2014, Radiation oncology.

[15]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[16]  G. Berchem,et al.  The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity , 2013, Front. Immunol..

[17]  P. Morris,et al.  Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[18]  Chi Man Tsang,et al.  Efficient Immortalization of Primary Nasopharyngeal Epithelial Cells for EBV Infection Study , 2013, PloS one.

[19]  F. Marincola,et al.  Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients , 2013, Journal of Translational Medicine.

[20]  Tao-Tao Liu,et al.  Intratumor Hypoxia Promotes Immune Tolerance by Inducing Regulatory T Cells via TGF-β1 in Gastric Cancer , 2013, PloS one.

[21]  M. Cheng,et al.  NK cell-based immunotherapy for malignant diseases , 2013, Cellular and Molecular Immunology.

[22]  C. Yee,et al.  Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. , 2013, Cancer research.

[23]  L. Wang,et al.  Membrane‐bound interleukin‐21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT‐3 activation , 2013, Clinical and experimental immunology.

[24]  R. Nahta.  Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer , 2012, ISRN oncology.

[25]  D. Heo,et al.  Abstract 3514:Ex vivoactivation and expansion of natural killer cells from advanced cancer patients with feeder cells from healthy volunteers , 2012 .

[26]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[27]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[28]  T. Cotechini,et al.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. , 2011, Cancer research.

[29]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[30]  S. Rosenberg,et al.  Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.

[31]  A. Ashkar,et al.  Stimulating natural killer cells to protect against cancer: recent developments , 2011, Expert review of clinical immunology.

[32]  Dean Anthony Lee,et al.  Expansion, purification, and functional assessment of human peripheral blood NK cells. , 2011, Journal of visualized experiments : JoVE.

[33]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[34]  A. Gratwohl,et al.  Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. , 2010, Cytotherapy.

[35]  M. Karamouzis,et al.  A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.

[36]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  J. Skepper,et al.  Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands* , 2010, The Journal of Biological Chemistry.

[38]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[39]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[40]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[41]  Stefano Papa,et al.  NK Cells and Cancer1 , 2007, The Journal of Immunology.

[42]  Sun-Hee Kim,et al.  Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation , 2006, Experimental & Molecular Medicine.

[43]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[44]  F. Penault-Llorca,et al.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.

[45]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[46]  H. Harada,et al.  Autologous natural killer cell therapy for human recurrent malignant glioma. , 2004, Anticancer research.

[47]  R. Weinberg,et al.  Reconstruction of functionally normal and malignant human breast tissues in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Caligiuri,et al.  In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. , 2002, Blood.

[49]  H. Kirchner,et al.  Large-scale generation of natural killer lymphocytes for clinical application. , 2002, Journal of hematotherapy & stem cell research.

[50]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[51]  H. Ljunggren,et al.  A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. , 2001, Human immunology.

[52]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[53]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[54]  L. Lanier,et al.  Analysis of the costimulatory role of IL-2 and IL-15 in initiating proliferation of resting (CD56dim) human NK cells. , 1996, Journal of immunology.

[55]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[57]  E. Lotzová,et al.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. , 1987, Journal of immunology.

[58]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[59]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Ashraf Khan,et al.  Theranostic and molecular classification of breast cancer. , 2014, Archives of Pathology & Laboratory Medicine.

[61]  B. Hennessy,et al.  HER2-family signalling mechanisms, clinical implications and targeting in breast cancer , 2014, Breast Cancer Research and Treatment.

[62]  W. Murphy,et al.  Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[63]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[64]  H. Heimpel,et al.  Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation , 2005, Annals of Hematology.

[65]  H. Klingemann,et al.  Ex vivo expansion of natural killer cells for clinical applications. , 2004, Cytotherapy.

[66]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.